Core Viewpoint - The company, He Yu-B (02256), has shown strong financial performance in its recent interim results, with significant revenue and profit growth, leading to a positive market reaction and stock price increase [1]. Financial Performance - The company reported a revenue of 612 million yuan for the first half of the year, representing a year-on-year increase of 21.5% [1]. - The net profit attributable to shareholders reached 328 million yuan, marking a year-on-year growth of 58.8% [1]. - The company has guided that its annual operating cash consumption will remain within 570 million yuan, indicating a potential for sustained profitability throughout the year [1]. Product Development and Pipeline - The company’s core dual pipeline is progressing smoothly, with the NDA for Pimiatinib accepted in China in June, and plans to submit a listing application in the U.S. in the second half of the year, with potential approvals expected in both China and the U.S. next year [1]. - In June, the company administered the first patient dose in China for Ipagufinib's registration clinical trial, and in July, it updated the Phase II clinical results of Ipagufinib combined with Atezolizumab at the ESMO-GI conference, showing an ORR of ≥50% and mPFS of ≥7 months in the 220mg BID dosage group [1]. - The company is continuously developing promising early-stage pipelines [1].
港股异动 和誉-B(02256)再涨超5% 默克行权收入超预期 上半年纯利同比增超58%